Current Assets
Trading Securities in Marketable Securities
AbbVie Trading Securities in Marketable Securities increased by 2.5% to $163.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.8%, from $157.00M to $163.00M. Over 5 years (FY 2020 to FY 2025), Trading Securities in Marketable Securities shows an upward trend with a 9.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ3 2018
Last reportedQ1 2026May 8, 2026
Metric ID:
trading_securities_in_marketable_securitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $118.00M | $132.00M | $149.00M | $147.00M | $148.00M | $143.00M | $129.00M | $115.00M | $124.00M | $131.00M | $159.00M | $161.00M | $160.00M | $153.00M | $169.00M | $157.00M | $166.00M | $172.00M | $159.00M | $163.00M |
| QoQ Change | — | +11.9% | +12.9% | -1.3% | +0.7% | -3.4% | -9.8% | -10.9% | +7.8% | +5.6% | +21.4% | +1.3% | -0.6% | -4.4% | +10.5% | -7.1% | +5.7% | +3.6% | -7.6% | +2.5% |
| YoY Change | — | — | — | — | +25.4% | +8.3% | -13.4% | -21.8% | -16.2% | -8.4% | +23.3% | +40.0% | +29.0% | +16.8% | +6.3% | -2.5% | +3.8% | +12.4% | -5.9% | +3.8% |
Range$115.00M – $172.00M
CAGR+7.0%
Avg YoY Growth+6.3%
Median YoY Growth+5.1%
Trading Securities in Marketable Securities at Other Companies
Frequently Asked Questions
- What is AbbVie's trading securities in marketable securities?
- AbbVie (ABBV) reported trading securities in marketable securities of $163.00M in Q1 2026.
- How has AbbVie's trading securities in marketable securities changed year-over-year?
- AbbVie's trading securities in marketable securities increased by 3.8% year-over-year, from $157.00M to $163.00M.
- What is the long-term trend for AbbVie's trading securities in marketable securities?
- Over 5 years (2020 to 2025), AbbVie's trading securities in marketable securities has grown at a 9.3% compound annual growth rate (CAGR), from $102.00M to $159.00M.